Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 893 (LINC00893), also known as EOLA1 divergent transcript (EOLA1-DT), is a member of the long non-coding RNA (lncRNA) class. These transcripts are over 200 nucleotides in length and do not code for proteins, but can regulate gene expression locally or at a distance in the genome[2]. Divergent lncRNAs are transcribed in close genomic proximity and in the opposite direction to adjacent protein-coding genes, often participating in transcriptional and epigenetic regulation[1]. The alias "CRC progression-associated lncRNA" suggests that LINC00893/EOLA1-DT may be involved in colorectal cancer, although its biological role, mechanisms, and potential as a biomarker or target remain largely uncharacterized in current literature. No drugs, direct mechanisms of action, or safety issues have been documented for this target[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 893 (LINC00893).